These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 17218777)
1. Active immunotherapy with 1E10 anti-idiotype vaccine in patients with small cell lung cancer: report of a phase I trial. Neninger E; Díaz RM; de la Torre A; Rives R; Díaz A; Saurez G; Gabri MR; Alonso DF; Wilkinson B; Alfonso AM; Combet T; Pérez R; Vázquez AM Cancer Biol Ther; 2007 Feb; 6(2):145-50. PubMed ID: 17218777 [TBL] [Abstract][Full Text] [Related]
2. Immune responses in breast cancer patients immunized with an anti-idiotype antibody mimicking NeuGc-containing gangliosides. Díaz A; Alfonso M; Alonso R; Saurez G; Troche M; Catalá M; Díaz RM; Pérez R; Vázquez AM Clin Immunol; 2003 May; 107(2):80-9. PubMed ID: 12763476 [TBL] [Abstract][Full Text] [Related]
3. An anti-idiotype vaccine elicits a specific response to N-glycolyl sialic acid residues of glycoconjugates in melanoma patients. Alfonso M; Díaz A; Hernández AM; Pérez A; Rodríguez E; Bitton R; Pérez R; Vázquez AM J Immunol; 2002 Mar; 168(5):2523-9. PubMed ID: 11859147 [TBL] [Abstract][Full Text] [Related]
4. Characterization of the antibody response against NeuGcGM3 ganglioside elicited in non-small cell lung cancer patients immunized with an anti-idiotype antibody. Hernández AM; Toledo D; Martínez D; Griñán T; Brito V; Macías A; Alfonso S; Rondón T; Suárez E; Vázquez AM; Pérez R J Immunol; 2008 Nov; 181(9):6625-34. PubMed ID: 18941253 [TBL] [Abstract][Full Text] [Related]
5. Generation of anti-Neu-glycolyl-ganglioside antibodies by immunization with an anti-idiotype monoclonal antibody: A self versus non-self-matter. Hernández AM; Rodríguez M; López-Requena A; Beausoleil I; Pérez R; Vázquez AM Immunobiology; 2005; 210(1):11-21. PubMed ID: 16076030 [TBL] [Abstract][Full Text] [Related]
6. 1E10 anti-idiotype vaccine in non-small cell lung cancer: experience in stage IIIb/IV patients. Alfonso S; Diaz RM; de la Torre A; Santiesteban E; Aguirre F; Pérez K; Rodríguez JL; Barroso Mdel C; Hernández AM; Toledo D; Gabri MR; Alonso DF; Viada C; Gómez RE; Suárez E; Vazquez AM; Perez R; Macias AE Cancer Biol Ther; 2007 Dec; 6(12):1847-52. PubMed ID: 18075301 [TBL] [Abstract][Full Text] [Related]
7. Combined therapeutic effect of a monoclonal anti-idiotype tumor vaccine against NeuGc-containing gangliosides with chemotherapy in a breast carcinoma model. Fuentes D; Avellanet J; Garcia A; Iglesias N; Gabri MR; Alonso DF; Vazquez AM; Perez R; Montero E Breast Cancer Res Treat; 2010 Apr; 120(2):379-89. PubMed ID: 19377876 [TBL] [Abstract][Full Text] [Related]
8. Cancer vaccines: an update with special focus on ganglioside antigens. Bitton RJ; Guthmann MD; Gabri MR; Carnero AJ; Alonso DF; Fainboim L; Gomez DE Oncol Rep; 2002; 9(2):267-76. PubMed ID: 11836591 [TBL] [Abstract][Full Text] [Related]
9. Come forth 1E10 anti-idiotype vaccine: delivering the promise to immunotherapy of small cell lung cancer. Manjili MH Cancer Biol Ther; 2007 Feb; 6(2):151-2. PubMed ID: 17426436 [No Abstract] [Full Text] [Related]
10. Anti-ganglioside anti-idiotypic monoclonal antibody-based cancer vaccine induces apoptosis and antiangiogenic effect in a metastatic lung carcinoma. Diaz Y; Gonzalez A; Lopez A; Perez R; Vazquez AM; Montero E Cancer Immunol Immunother; 2009 Jul; 58(7):1117-28. PubMed ID: 19066887 [TBL] [Abstract][Full Text] [Related]
11. Racotumomab for treating lung cancer and pediatric refractory malignancies. Gabri MR; Cacciavillano W; Chantada GL; Alonso DF Expert Opin Biol Ther; 2016; 16(4):573-8. PubMed ID: 26903265 [TBL] [Abstract][Full Text] [Related]
12. Generation and characterization of an anti-idiotype monoclonal antibody related to GM3(NeuGc) ganglioside. Rodríguez M; Llanes L; Pérez A; Pérez R; Vázquez AM Hybrid Hybridomics; 2003 Oct; 22(5):307-14. PubMed ID: 14678648 [TBL] [Abstract][Full Text] [Related]
13. Racotumomab - a novel anti-idiotype monoclonal antibody vaccine for the treatment of cancer. Gajdosik Z Drugs Today (Barc); 2014 Apr; 50(4):301-7. PubMed ID: 24918647 [TBL] [Abstract][Full Text] [Related]
14. Anti-NeuGcGM3 antibodies, actively elicited by idiotypic vaccination in nonsmall cell lung cancer patients, induce tumor cell death by an oncosis-like mechanism. Hernández AM; Rodríguez N; González JE; Reyes E; Rondón T; Griñán T; Macías A; Alfonso S; Vázquez AM; Pérez R J Immunol; 2011 Mar; 186(6):3735-44. PubMed ID: 21300821 [TBL] [Abstract][Full Text] [Related]
15. Gangliosides, Ab1 and Ab2 antibodies II. Light versus heavy chain: An idiotype-anti-idiotype case study. López-Requena A; Rodríguez M; de Acosta CM; Moreno E; Puchades Y; González M; Talavera A; Valle A; Hernández T; Vázquez AM; Pérez R Mol Immunol; 2007 Feb; 44(5):1015-28. PubMed ID: 16620986 [TBL] [Abstract][Full Text] [Related]
16. Syngeneic anti-idiotypic monoclonal antibodies to an anti-NeuGc-containing ganglioside monoclonal antibody. Vázquez AM; Pérez A; Hernández AM; Macías A; Alfonso M; Bombino G; Pérez R Hybridoma; 1998 Dec; 17(6):527-34. PubMed ID: 9890708 [TBL] [Abstract][Full Text] [Related]
17. NGcGM3 ganglioside: a privileged target for cancer vaccines. Fernandez LE; Gabri MR; Guthmann MD; Gomez RE; Gold S; Fainboim L; Gomez DE; Alonso DF Clin Dev Immunol; 2010; 2010():814397. PubMed ID: 21048926 [TBL] [Abstract][Full Text] [Related]
18. Chimeric anti-N-glycolyl-ganglioside and its anti-idiotypic MAbs: immunodominance of their variable regions. López-Requena A; Mateo de Acosta C; Pérez A; Valle A; Lombardero J; Sosa K; Pérez R; Vázquez AM Hybrid Hybridomics; 2003 Aug; 22(4):235-43. PubMed ID: 14511569 [TBL] [Abstract][Full Text] [Related]
19. Immunogenetic analysis of variable regions encoding AB1 and gamma-type AB2 antibodies from the NeuGc-containing ganglioside family. Perez A; Lombardero J; Mateo C; Mustelier G; Alfonso M; Vazquez AM; Perez R Hybridoma; 2001 Aug; 20(4):211-21. PubMed ID: 11604106 [TBL] [Abstract][Full Text] [Related]
20. Immune responses in patients with T-cell lymphoma treated with an anti-idiotype antibody mimicking a highly restricted T-cell antigen. Foon KA; Oseroff AR; Vaickus L; Greenberg SJ; Russell D; Bernstein Z; Pincus S; Köhler H; Seon BK; Tahaoglu E Clin Cancer Res; 1995 Nov; 1(11):1285-94. PubMed ID: 9815923 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]